ArticleThe Journal of investigative dermatology2015
Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.
Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety.Current therapeutic research, clinical and experimental · 2026Review
- Phototherapy as an alternative in the treatment of chronic spontaneous urticaria.Frontiers in allergy · 2024Review
- Self-reactive IgE and anti-IgE therapy in autoimmune diseases.Frontiers in pharmacology · 2023Review
- Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma-A Romanian Perspective.Children (Basel, Switzerland) · 2021Article
- IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Article
- Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic.The World Allergy Organization journal · 2021Article
- Article
- Dendritic Cell-Mediated Th2 Immunity and Immune Disorders.International journal of molecular sciences · 2019Review
- Biological therapies for atopic dermatitis: An update.Experimental and therapeutic medicine · 2019Review
- Omalizumab in children with severe allergic disease: a case series.Italian journal of pediatrics · 2019Article
- Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system.ClinicoEconomics and outcomes research : CEOR · 2016Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.
Indexed as
Identifiers
25501377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.